Denali Therapeutics announces $250M public offering of common stock

Denali Therapeutics Inc.

Denali to sell $250M of common stock; underwriters have 30-day option for additional 15%.
Goldman Sachs, J.P. Morgan, and Jefferies act as joint book-running managers for the offering.
Preliminary cash, cash equivalents, and marketable securities estimated at $1.11B as of Sep 30, 2022.
Company has no approved products and expects to continue incurring significant net losses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.